Skip to content
Home/Companies/Biotech/Complix
Complix

Complix

Biotech·Belgium·Exited 2017·Held 4yr
Entry
2013
Hold
4yr
Exit
2017

Who owns Complix?

Complix is a Belgian Biotech company, now owned by Merck KGaA, which acquired it in 2017 from Andera Partners.

Hand-verified · updated 2026-04-21

Open JSON · CC-BY
Andera Partners
Investor
Andera Partners
BioDiscovery 4 · 2013 · VC

Key facts

HQBelgium
SectorBiotech
Websitewww.complix.com
Exit Type
Trade Sale
Buyer
Merck KGaA
Exit Year
2017

More from BioDiscovery 4

Other portfolio companies in the same fund.

Inotrem
Active
BiotechFrance
MedDay Pharmaceuticals
Exited 2021
BiotechFrance· 2016
Verona Pharma
Verona Pharma
Exited 2017
BiotechUK· 2016
Autonomic Technologies
Exited 2020
MedTechUS· 2015
to Unity HA
Gamamabs
Active
BiotechFrance· 2015
ReViral
Exited 2022
BiotechUK· 2015
to Pfizer

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Complix?

Complix is now owned by Merck KGaA, which acquired it in 2017 from Andera Partners.

When did Merck KGaA acquire Complix?

Merck KGaA acquired Complix in 2017, buying from Andera Partners.

Who did Complix sell to?

Andera Partners sold Complix to Merck KGaA in 2017 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue